Trials / Recruiting
RecruitingNCT06747949
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 844 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dazodalibep | Dazodalibep will be given intravenously (IV). |
Timeline
- Start date
- 2025-02-25
- Primary completion
- 2029-12-11
- Completion
- 2029-12-11
- First posted
- 2024-12-24
- Last updated
- 2026-04-07
Locations
168 sites across 26 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, New Zealand, Peru, Poland, Portugal, Serbia, Slovenia, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06747949. Inclusion in this directory is not an endorsement.